Join

Compare · DNA vs GILD

DNA vs GILD

Side-by-side comparison of Ginkgo Bioworks Holdings Inc. (DNA) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both DNA and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
  • GILD is the larger of the two at $162.43B, about 310.0x DNA ($523.9M).
  • Over the past year, DNA is up 38.8% and GILD is up 27.5% - DNA leads by 11.3 points.
  • GILD has been more active in the news (12 items in the past 4 weeks vs 11 for DNA).
  • GILD has more recent analyst coverage (25 ratings vs 17 for DNA).
PerformanceDNA+38.83%GILD+27.50%
2025-05-01+0.00%2026-05-01
MetricDNAGILD
Company
Ginkgo Bioworks Holdings Inc.
Gilead Sciences Inc.
Price
$9.69+14.67%
$131.63+0.60%
Market cap
$523.9M
$162.43B
1M return
+42.92%
-6.18%
1Y return
+38.83%
+27.50%
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NYSE
NASDAQ
IPO
2021
1992
News (4w)
11
12
Recent ratings
17
25
DNA

Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings, Inc. develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is based in Boston, Massachusetts.

GILD

Gilead Sciences Inc.

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.